Ming-Chun Hsu

2.3k total citations · 1 hit paper
14 papers, 1.7k citations indexed

About

Ming-Chun Hsu is a scholar working on Immunology, Pediatrics, Perinatology and Child Health and Pathology and Forensic Medicine. According to data from OpenAlex, Ming-Chun Hsu has authored 14 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 5 papers in Pediatrics, Perinatology and Child Health and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Ming-Chun Hsu's work include Psoriasis: Treatment and Pathogenesis (14 papers), Pharmaceutical studies and practices (5 papers) and Autoimmune Bullous Skin Diseases (4 papers). Ming-Chun Hsu is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (14 papers), Pharmaceutical studies and practices (5 papers) and Autoimmune Bullous Skin Diseases (4 papers). Ming-Chun Hsu collaborates with scholars based in United States, Canada and Germany. Ming-Chun Hsu's co-authors include Richard G. Langley, Kristian Reich, Philippe Szapary, Mark Lebwohl, Gerald G. Krueger, Newman Yeilding, Kim Papp, Cynthia Guzzo, Shu Li and Lisa T. Dooley and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and Journal of the American Academy of Dermatology.

In The Last Decade

Ming-Chun Hsu

14 papers receiving 1.7k citations

Hit Papers

Efficacy and safety of ustekinumab, a human interleukin-1... 2008 2026 2014 2020 2008 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
    2008 1.1k citations Kim Papp, Richard G. Langley et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ming-Chun Hsu United States 9 1.5k 824 323 281 270 14 1.7k
Jeffrey Crowley United States 24 1.5k 1.0× 866 1.1× 407 1.3× 312 1.1× 218 0.8× 64 1.9k
Mary Flack United States 11 1.3k 0.9× 822 1.0× 194 0.6× 200 0.7× 311 1.2× 25 1.5k
Isabelle Hampele United States 6 1.3k 0.9× 751 0.9× 344 1.1× 261 0.9× 256 0.9× 8 1.6k
Zenas Z N Yiu United Kingdom 21 1.2k 0.8× 898 1.1× 308 1.0× 198 0.7× 286 1.1× 72 1.8k
Thomas Salko United States 5 1.3k 0.8× 720 0.9× 333 1.0× 244 0.9× 253 0.9× 5 1.6k
H. Bachelez France 16 1.2k 0.8× 822 1.0× 209 0.6× 270 1.0× 300 1.1× 41 1.4k
Michael Song United States 22 2.1k 1.4× 1.3k 1.5× 682 2.1× 298 1.1× 450 1.7× 49 2.5k
Gregory Kricorian United States 14 1.4k 0.9× 718 0.9× 387 1.2× 200 0.7× 278 1.0× 23 1.7k
R. You Switzerland 11 1.2k 0.8× 812 1.0× 235 0.7× 274 1.0× 175 0.6× 17 1.3k
Yin You United States 17 1.0k 0.7× 478 0.6× 341 1.1× 132 0.5× 130 0.5× 34 1.2k

Countries citing papers authored by Ming-Chun Hsu

Since Specialization
Citations

This map shows the geographic impact of Ming-Chun Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming-Chun Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming-Chun Hsu more than expected).

Fields of papers citing papers by Ming-Chun Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming-Chun Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming-Chun Hsu. The network helps show where Ming-Chun Hsu may publish in the future.

Co-authorship network of co-authors of Ming-Chun Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Ming-Chun Hsu. A scholar is included among the top collaborators of Ming-Chun Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming-Chun Hsu. Ming-Chun Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Gooderham, Melinda, Robert Bissonnette, Yu‐Huei Huang, et al.. (2025). Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites. NEJM Evidence. 4(12). EVIDoa2500155–EVIDoa2500155. 1 indexed citations
2.
Blauvelt, Andrew, April W. Armstrong, Richard G. Langley, et al.. (2021). Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. Journal of Dermatological Treatment. 33(4). 2317–2324. 21 indexed citations
3.
Langley, Richard G., Petr Arenberger, Susan Flavin, et al.. (2020). 15302 Psoriasis area and severity index component improvements at week 48 in patients treated with guselkumab compared with secukinumab: Findings from the ECLIPSE study. Journal of the American Academy of Dermatology. 83(6). AB34–AB34. 3 indexed citations
4.
5.
Reich, Kristian, Alice B. Gottlieb, Lyn Guenther, et al.. (2020). 15188 Clinical responses by self-reported PsA status at baseline among patients with moderate to severe psoriasis treated with guselkumab versus secukinumab: Week 48 results from the ECLIPSE study. Journal of the American Academy of Dermatology. 83(6). AB31–AB31. 1 indexed citations
6.
Reich, Kristian, April W. Armstrong, Richard G. Langley, et al.. (2019). Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. The Lancet. 394(10201). 831–839. 259 indexed citations
7.
8.
Dai, Ying‐Xiu, Ming-Chun Hsu, Hsiao‐Yun Hu, et al.. (2018). The Risk of Mortality among Psoriatic Patients with Varying Severity: A Nationwide Population-Based Cohort Study in Taiwan. International Journal of Environmental Research and Public Health. 15(12). 2622–2622. 17 indexed citations
9.
Blauvelt, Andrew, Laura K. Ferris, Paul S. Yamauchi, et al.. (2017). Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR). British Journal of Dermatology. 177(6). 1552–1561. 45 indexed citations
10.
Langley, Richard G., Mark Lebwohl, Gerald G. Krueger, et al.. (2014). Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up. British Journal of Dermatology. 172(5). 1371–1383. 141 indexed citations
11.
Brodmerkel, Carrie, Eric Wadman, Richard G. Langley, et al.. (2013). Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.. PubMed. 12(10). 1122–9. 51 indexed citations
12.
Kimball, Alexa B., Philippe Szapary, Ulrich Mrowietz, et al.. (2011). Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology. 67(1). 76–85. 103 indexed citations
13.
Papp, Kim, Richard G. Langley, Mark Lebwohl, et al.. (2008). Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). The Lancet. 371(9625). 1675–1684. 1067 indexed citations breakdown →
14.
Menter, Alan, Kristian Reich, Alice B. Gottlieb, et al.. (2008). Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.. PubMed. 7(12). 1137–46. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey Crowley Breakdown of academic impact, for papers by Mary Flack Breakdown of academic impact, for papers by Isabelle Hampele Breakdown of academic impact, for papers by Zenas Z N Yiu Breakdown of academic impact, for papers by Thomas Salko Breakdown of academic impact, for papers by H. Bachelez Breakdown of academic impact, for papers by Michael Song Breakdown of academic impact, for papers by Gregory Kricorian Breakdown of academic impact, for papers by R. You Breakdown of academic impact, for papers by Yin You
Rankless by CCL
2026